Alzheimer

The developed solution is an innovative web application that leverages advanced Explainable Machine Learning algorithms to enable rapid, early diagnosis of Alzheimer’s disease, anticipating symptomatic onset by up to 18 months. At the core of the technology is the integration of a gender-specific approach combined with the exclusive use of non-invasive, cost-effective data, such as neuropsychological test scores.

The technology is an ultra-sensitive optical biosensor based on the FRET principle, designed for identifying the initial, pre-aggregated pathological form of the Tau protein (CST). The innovation lies in the ability to detect specific conformational changes (CST), providing a molecular advantage over concentration-only tests.

In vitro validation (TRL 3) has been successfully completed, demonstrating the sensor's effectiveness on: